Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2004-02-20
2010-02-16
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C530S391700
Reexamination Certificate
active
07662387
ABSTRACT:
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
REFERENCES:
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0157782 (2004-08-01), Doronina et al.
patent: 2005/0113308 (2005-05-01), Senter et al.
patent: 2005/0118656 (2005-06-01), Terrett
patent: 2005/0123547 (2005-06-01), Terrett
patent: 2005/0191299 (2005-09-01), Swamy et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0083736 (2006-04-01), Law et al.
patent: 2007/0292422 (2007-12-01), Law et al.
patent: 2008/0025989 (2008-01-01), Law et al.
patent: 2008/0138341 (2008-06-01), Law et al.
patent: 2008/0138343 (2008-06-01), Law et al.
patent: 2008/0226657 (2008-09-01), Doronina et al.
patent: 2008/0248051 (2008-10-01), Doronina et al.
patent: 2008/0248053 (2008-10-01), Doronina et al.
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/026577 (2003-04-01), None
patent: WO 03/046581 (2003-06-01), None
patent: WO 2004/010957 (2004-02-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2005/081711 (2005-09-01), None
patent: WO 2006/044643 (2006-04-01), None
patent: WO 2006/113909 (2006-10-01), None
Hintzen RQ, Lens SM, Beckmann MP,Goodwin RG, Lynch D, van Lier RA. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. Feb. 15, 1994;152(4):1762-73.
Lens et al. British Journal of Hematology. 1999. 106, p. 491-503.
MacCallum et al. J Mol Biol. Oct. 11, 1996;262(5):732-45.
De Pascalis et al. J Immunol. Sep. 15, 2002;169(6):3076-84.
Casset et al. Biochem Biophys Res Commun. Jul. 18, 2003;307(1):198-205.
Vajdos et al. J Mol Biol. Jul. 5, 2002;320(2):415-28.
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79(6) p. 1979-83.
Holm et al. Mol Immunol. Feb. 2007;44(6):1075-84. Epub Sep. 20, 2006.
Chen et al. J Mol Biol. Nov. 5, 1999;293(4):865-81.
Wu et al. J Mol Biol. Nov. 19, 1999;294(1):151-62.
Hintzen et al. J lmmunol. Feb. 15, 1994;152(4):1762-73.
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 21(7):778-784 (2003) + erratum: 21(8):941 (2003).
Oelke et al., “Overexpression of CD70 and Overstimulations of IgG Synthesis by Lupus T Cells and T Cells Treated With DNA Methylation Inhibitors,”Arthritis&Rheumatism, 50(6):1850-1860 (2004).
Agathanggelou et al., “Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells,”Am J. Pathol., 147(4):1152-1160 (1995).
Agematsu et al., “Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction,” Blood 91(1):173-180 (1998).
Agematsu et al., “B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production,”Eur. J. Immunol. 27(8):2073-2079 (1997).
Akiba et al., “Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis,”J. Exp. Med. 191(2):375-380 (2000).
Baert, et al., “Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crogn's Disease” N Engl J Med, 348(7):601-608 (2003).
Bahler et al., “Clonal evolution of a follicular lymphoma: evidence for antigen selection,”PNAS, 89(15):6770-6774 (1992).
Bahler et al., “Antigen selection in human lymphomagenesis ”Cancer Res., 52(19 Suppl.):5547s-5551s (1992).
Bowman et al., “The cloning of CD70 and its identification as the ligand for CD27,”J. Immunol., 152(4):1756-1761 (1994).
Brugnoni et al., “CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation,”Immunol. Lett., 55(2):99-104 (1997).
Carter, P., “Improving the Efficacy of Antibody-Based Cancer Therapies,” Nature Reviews, (1):118-129 (2001).
Coleman, PM., “Effects of aminio acid sequence changes on antibody-antigen interactions” Res. Immunology, 145:33-36 (1994).
De Jong et al., “Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors,”J. Immunol. 146(8):2488-2494 (1991).
Den Haan et al., “Identification of a graft versus host disease-associated human minor histocompatibility antigen,”Science268(5216):1476-1480 (1995).
Dillman, R. O., “Monoclonal Antibodies for Treating Cancer,”Ann. Int. Med. 111:592-603 (1989).
European Search Report of Mar. 12, 2007 for European Application EP 04 71 3441.
Emery, et al., “Humanised monoclonal antibodies for therapeutic applications” Exp. Opin. Invest. Drugs, 3(3):241-251 (1994).
Giralt et al., “Leukemia relapse after allogeneic bone marrow transplantation: a review,” Blood 84(11):3603-3612 (1994).
Goodwin et al., “Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor,”Cell, 73(3):447-456 (1993).
Gordon et al., “Humanized Anti-CD70 Auristatin Antibody-Drug Conjugates Show Potent in Vitro Cytotoxicity in Renal Cell Carcinoma Primary Cultures Established from Patient Tumor Isolates,” Abstract No. 3733, 97th Annual Meeting of the American Association for Cancer Research, Apr. 1-5, 2006, Washington, D.C.
Gravestein et al., “Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family,”Eur. J. lmmunol., 23(4):943-950 (1993).
Gravestein et al., “Novel mAbs reveal potent co-stimulatory activity of murine CD27,”Int. Immunol., 7(4):551-55 (1995).
Gruss et al., “Pathophysiology of Hodgkin's disease: functional and molecular aspects,”Baillieres Clin. Haematol., 9(3):417-446 (1996).
Held-Feindt et al., “CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors”Int. J. Cancer, 98(3):352-356 (2002).
Hintzen et al., “CD70 represents the human ligand for CD 27,”Int. Immunol., 6(3):477-480 (1994).
Hintzen et al., “CD27; marker and mediator of T-cell activation?,”lmmunol. Today, 15(7):307-311 (1994).
Hintzen et al., “Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation,”J. Immunol., 154(6):2612-2623 (1995).
Hintzen et al., “Regulation of CD27 expression on subsets of mature T-lymphocytes”J. Immunol., 151(5):2426-2435 (1993).
Hintzen et al., “A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex,” J. Immunol. 147(1):29-35 (1991).
Hishima et al., “CD70 expression in thymic carcinoma,”Am. J. Sum. Pathol. 24(5):742-746 (2000).
Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1” Mol Immunol. 44:1075-84.(2007) Epub 2006.
Jacquot et al., “CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling,”J. lm
Law Che-Leung
Pestano Linda A.
Scholler Nathalie
Wahl Alan F.
Helms Larry R.
Natarajan Meera
Seattle Genetics
LandOfFree
Anti-cd70 antibody-drug conjugates and their use for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cd70 antibody-drug conjugates and their use for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cd70 antibody-drug conjugates and their use for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211977